Hughes DA - Search Results

1

European expert consensus statement on therapeutic goals in Fabry disease.

Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, Fomin VV, Germain DP, Hughes DA, Jovanovic A, Kantola I, Linhart A, Mignani R, Monserrat L, Namdar M, Nowak A, Oliveira JP, Ortiz A, Pieroni M, Spada M, Tylki-Szymańska A, Tøndel C, Viana-Baptista M, Weidemann F, Hilz MJ. Wanner C, et al. Among authors: hughes da. Mol Genet Metab. 2018 Jul;124(3):189-203. doi: 10.1016/j.ymgme.2018.06.004. Epub 2018 Jun 12. Mol Genet Metab. 2018. PMID: 30017653 Review.

2

Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease.

Shah JS, Hughes DA, Sachdev B, Tome M, Ward D, Lee P, Mehta AB, Elliott PM. Shah JS, et al. Among authors: hughes da. Am J Cardiol. 2005 Sep 15;96(6):842-6. doi: 10.1016/j.amjcard.2005.05.033. Am J Cardiol. 2005. PMID: 16169374

3

Early therapeutic intervention in females with Fabry disease?

Hughes DA. Hughes DA. Acta Paediatr. 2008 Apr;97(457):41-7. doi: 10.1111/j.1651-2227.2008.00649.x. Acta Paediatr. 2008. PMID: 18339187 Review.

4

The binary endocardial appearance is a poor discriminator of Anderson-Fabry disease from familial hypertrophic cardiomyopathy.

Kounas S, Demetrescu C, Pantazis AA, Keren A, Lee PJ, Hughes D, Mehta A, Elliott PM. Kounas S, et al. J Am Coll Cardiol. 2008 May 27;51(21):2058-61. doi: 10.1016/j.jacc.2008.02.046. J Am Coll Cardiol. 2008. PMID: 18498962 Free article.

5

Does geographical location influence the phenotype of Fabry disease in women in Europe?

Barba-Romero MA, Deegan P, Giugliani R, Hughes D. Barba-Romero MA, et al. Clin Genet. 2010 Feb;77(2):131-40. doi: 10.1111/j.1399-0004.2009.01345.x. Clin Genet. 2010. PMID: 20096069

6

Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT).

Linthorst GE, Germain DP, Hollak CE, Hughes D, Rolfs A, Wanner C, Mehta A; European Medicines Agency. Linthorst GE, et al. Mol Genet Metab. 2011 Jan;102(1):99-102. doi: 10.1016/j.ymgme.2010.11.155. Epub 2010 Nov 30. Mol Genet Metab. 2011. PMID: 21123099

7

Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS--the Fabry Outcome Survey.

Hughes DA, Barba Romero MÁ, Hollak CE, Giugliani R, Deegan PB. Hughes DA, et al. Mol Genet Metab. 2011 Jul;103(3):207-14. doi: 10.1016/j.ymgme.2011.03.022. Epub 2011 Mar 31. Mol Genet Metab. 2011. PMID: 21543245 Clinical Trial.

8

A distinct urinary biomarker pattern characteristic of female Fabry patients that mirrors response to enzyme replacement therapy.

Kistler AD, Siwy J, Breunig F, Jeevaratnam P, Scherl A, Mullen W, Warnock DG, Wanner C, Hughes DA, Mischak H, Wüthrich RP, Serra AL. Kistler AD, et al. Among authors: hughes da. PLoS One. 2011;6(6):e20534. doi: 10.1371/journal.pone.0020534. Epub 2011 Jun 15. PLoS One. 2011. PMID: 21698285 Free PMC article.

9

Cystatin C and NT-proBNP as prognostic biomarkers in Fabry disease.

Torralba-Cabeza MÁ, Olivera S, Hughes DA, Pastores GM, Mateo RN, Pérez-Calvo JI. Torralba-Cabeza MÁ, et al. Among authors: hughes da. Mol Genet Metab. 2011 Nov;104(3):301-7. doi: 10.1016/j.ymgme.2011.06.021. Epub 2011 Jul 1. Mol Genet Metab. 2011. PMID: 21795086

10

Incidence and predictors of anti-bradycardia pacing in patients with Anderson-Fabry disease.

O'Mahony C, Coats C, Cardona M, Garcia A, Calcagnino M, Murphy E, Lachmann R, Mehta A, Hughes D, Elliott PM. O'Mahony C, et al. Europace. 2011 Dec;13(12):1781-8. doi: 10.1093/europace/eur267. Epub 2011 Aug 18. Europace. 2011. PMID: 21856674

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

527 results

Search Page

Filters